Protai

Executive Summary

Protai is an Israeli AI-driven drug discovery company combining deep proteomics and structural AI to map disease-specific protein states. Its proprietary AIMS™ platform leverages mass spectrometry-derived structural data to design selective modulators for challenging oncology and immunology targets. Founded in 2020, the company operates a precision-medicine pipeline and offers its platform to external partners. Currently at preclinical stage with 10–50 employees, Protai focuses on early-stage assets with potential for high specificity and reduced toxicity. The company's integrated approach addresses a critical gap in drug discovery by capturing protein conformational changes in disease, enabling the development of more effective therapeutics. With no disclosed funding rounds or valuation, Protai remains a private, stealthy player in the AI-biotech space, positioning itself for future partnerships or lead optimization milestones.

Upcoming Catalysts (preview)

• Q3 2026Lead program nomination or advancement to IND-enabling studies55% success
• Q4 2026Pharmaceutical partnership or licensing deal for AIMS platform60% success
• Q2 2026Presentation of preclinical data at a major oncology or immunology conference75% success